Iveric Bio Reports 24-Month Results of Izervay (avacincaptad pegol) for Geographic Atrophy

Share this
Iveric Bio

Iveric Bio Reports 24-Month Results of Izervay (avacincaptad pegol) for Geographic Atrophy


  • The 24mos. results from the P-III trial evaluating Izervay (IVT) in 448 patients with GA secondary to AMD. The trial met the primary objective of reducing the rate of GA growth in patients treated with Izervay (monthly dosing regimen) vs sham at 24mos. while treatment effect with every other month dosing regimen showed a similar reduction in the rate of GA growth
  • The safety was consistent with prior reported 12mos. data, with no new safety signals, no cases of occlusive or non-occlusive retinal vasculitis or ischemic neuropathy were reported, rate of choroidal neovascularization (CNV) was 12% vs 9%
  • Izervay was approved in the US on Aug 2023 for GA secondary to AMD and is currently under the EMA’s review

Ref: PR Newswire | Image: Iveric Bio

Rewlated News:- Iveric Bio Reports EMA Acceptance of MAA for Avacincaptad Pegol to Treat Geographic Atrophy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 


Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions